Cancer Trial

Genmab Stock Surges 29% to a Record: Cancer Combo Halves the Risk of Death

2026-10-28

Genmab (NASDAQ: GMAB) stock surged about 29% in U.S. trading on Wednesday, October 28, 2026, after the Danish drugmaker said its experimental cancer treatment petosemtamab, combined with Merck's Ke...